缬基内酯 | 113276-96-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 缬基内酯
• 英文名称: (2S,2'S,3'S)-1-(3-hexyl-4-oxooxetan-2-yl)heptan-2-yl (S)-N-formyl-3-methylbutanoate
• 英文别名: (2S,2'S,3'S)-1-(3'-hexyl-4'-oxooxetan-2'-yl)heptan-2-yl (S)-N-formyl-valinate；valilactone；(-)-valilactone；(S)-((S)-1-((2S,3S)-3-hexyl-4-oxooxetan-2-yl)heptan-2-yl) 2-methanamido-3-methylbutanoate；N-formyl-L-valine-(S)-1-[[(2S,3S)-3-hexyl-4-oxo-2-oxetanyl]methyl]hexyl ester；[(2S)-1-[(2S,3S)-3-hexyl-4-oxooxetan-2-yl]heptan-2-yl] (2S)-2-formamido-3-methylbutanoate
• CAS: 113276-96-3
• 化学式: C₂₂H₃₉NO₅
• 分子量: 397.555
• InChiKey: WWGVIIVMPMBQFV-MUGJNUQGSA-N

物化性质

• 溶解度：
  DMF：25mg/mL； DMSO：25mg/mL； DMSO:PBS (pH 7.2) (1:2)：0.3 mg/ml；乙醇：10mg/mL

计算性质

• 辛醇/水分配系数(LogP)：
  6.4
• 重原子数：
  28
• 可旋转键数：
  16
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  81.7
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  CBZ-L-缬氨酸 在 palladium on activated charcoal 4-二甲氨基吡啶 、 氢气 、 N,N'-二环己基碳二亚胺 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 生成 缬基内酯
  参考文献：
  名称：

  使用π-烯丙基三羰基铁内酯配合物合成β-内酯酯酶抑制剂valilactone。

  摘要：

  据报道，酯酶抑制剂戊内酯（1）的合成是利用π-烯丙基三羰基铁内酯配合物与硝酸铈铵的氧化，得到固有的β-内酯环。

  DOI：

  10.1016/s0040-4039(00)78809-5

文献信息

• BETA-LACTONE COMPOUNDS
  申请人：Smith Jeffrey W.

  公开号：US20090124681A1

  公开（公告）日：2009-05-14

  The present invention provides compounds having the general structure A, or a pharmaceutically acceptable derivatives thereof: wherein R is an alkyl group, and R 1 comprises at least one moiety selected from a group consisting of an alkyl, an alkenyl, an aryl, a heterocycle, hydroxyl, ester, amido, aldehyde, and a halogen.

  本发明提供具有一般结构A的化合物，或其药学上可接受的衍生物：其中R是烷基基团，R1包括至少一种从烷基、烯基、芳基、杂环、羟基、酯、酰胺、醛基和卤素组成的基团。
• BETA-LACTONES AS ANTIBACTERIAL AGENTS
  申请人：Sieber Stephan A.

  公开号：US20110196027A1

  公开（公告）日：2011-08-11

  The present invention relates to specific beta-lactone compounds and compositions thereof for the treatment of infections, such as, e.g., infections with bacteria or infections with protozoa, in particular infections with Gram-positive and/or Gram-negative bacteria and of infectious diseases caused by or related to Gram-positive and/or Gram-negative bacteria, and to the modulation of virulence of Gram-positive and/or Gram-negative bacteria or of protozoa by specific beta-lactone compounds. The invention further relates to the use of the compounds or compositions for preventing or eliminating biofilms.

  本发明涉及特定的β-内酰胺类化合物及其组合物，用于治疗感染，例如细菌感染或原虫感染，特别是革兰氏阳性和/或革兰氏阴性细菌感染以及由革兰氏阳性和/或革兰氏阴性细菌引起或相关的传染病，并且涉及通过特定的β-内酰胺类化合物调节革兰氏阳性和/或革兰氏阴性细菌或原虫的毒力。本发明还涉及使用这些化合物或组合物预防或消除生物膜。
• Method and composition for reducing sebum secretion in mammals
  申请人：——

  公开号：US20030054020A1

  公开（公告）日：2003-03-20

  This invention relates to reducing sebum production on the skin using methods and compositions containing a surfactant, a chylomicron disrupter, a skin penetration enhancer, and an anti-androgenic compound. In a preferred embodiment, the composition contains the surfactant as a mixture of polyoxyethylene compounds and the anti-androgenic agent as a mixture of saw palmetto extract and nettle extract.

  本发明涉及使用含有表面活性剂、乳糜微粒干扰物、皮肤渗透促进剂和抗雄激素化合物的方法和组合物减少皮肤皮脂分泌。在一个优选的实施方案中，组合物中的表面活性剂是聚氧乙烯化合物的混合物，抗雄激素剂是锯棕榈提取物和荨麻提取物的混合物。
• Material for odor control
  申请人：Dutkiewicz K. Jacek

  公开号：US20060029567A1

  公开（公告）日：2006-02-09

  The present invention is directed to materials containing an enzyme inhibitor, including treated fibers, nonwovens, functional particles and processes for making these materials. These materials are useful in reducing or delaying onset of odor generation from various waste materials including human and animal elimination products.

  本发明涉及含有酶抑制剂的材料，包括经过处理的纤维、无纺布、功能性微粒以及制造这些材料的工艺。这些材料可用于减少或延缓包括人类和动物排泄物在内的各种废物产生臭味。
• Asymmetric synthesis of tetrahydrolipstatin and valilactone
  作者：Stephen C. Case-Green、Stephen G. Davies、Paul M. Roberts、Angela J. Russell、James E. Thomson

  DOI：10.1016/j.tetasy.2008.11.012

  日期：2008.11

  The highly diastereoselective aldol reaction between acyl complexes of the iron chiral auxiliary [(eta(5)-C5H5)Fe(CO)(PPh3)] and beta-hydroxy aldehydes (obtained via a Noyori asymmetric hydrogenation), followed by a tandem oxidative decomplexation-cyclisation process gives access to beta-substituted and alpha,beta-disubstituted beta-lactones in high ee. This methodology has been employed in the asymmetric syntheses of tetra hydrolipstatin and valilactone. (C) 2008 Elsevier Ltd. All rights reserved.